Engineering of Vesicular Stomatitis Virus (VSV) for Modulating Cell Death and Antitumor Immunity
- PMID: 40515910
- DOI: 10.1007/978-1-0716-4615-1_15
Engineering of Vesicular Stomatitis Virus (VSV) for Modulating Cell Death and Antitumor Immunity
Abstract
Vesicular stomatitis virus (VSV), a negative-sense RNA virus, has emerged as a versatile platform for oncolytic virotherapy and vaccine development. Numerous advantages, such as a broad host range, rapid replication, and simple and easily modifiable genomes, make it an attractive candidate for both the treatment and prevention of infectious diseases and tumors. Advances in molecular biology techniques, particularly reverse genetics and synthetic biology, have facilitated the precise engineering of VSV genomes, thereby significantly expanding their applications in cancer therapeutics. One of the most common antitumor strategies is to promote tumor cell death. Numerous studies have shown that engineered VSV with cell death elements has considerable antitumor efficacy. This chapter provides a comprehensive overview of VSV engineering techniques, focusing specifically on the incorporation of the proapoptotic gene XAF1, along with detailed experimental procedures. The goal of these approaches is to increase the efficacy of VSV in antitumor immunity and other therapeutic domains.
Keywords: Antitumor immunity; Cell death; Reverse genetic system; VSV.
© 2025. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Employing the Oncolytic Vesicular Stomatitis Virus in Cancer Virotherapy: Resistance and Clinical Considerations.Viruses. 2024 Dec 25;17(1):16. doi: 10.3390/v17010016. Viruses. 2024. PMID: 39861805 Free PMC article. Review.
-
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.J Gen Virol. 2012 Dec;93(Pt 12):2529-2545. doi: 10.1099/vir.0.046672-0. Epub 2012 Oct 10. J Gen Virol. 2012. PMID: 23052398 Free PMC article. Review.
-
Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.Viruses. 2018 Feb 23;10(2):90. doi: 10.3390/v10020090. Viruses. 2018. PMID: 29473868 Free PMC article. Review.
-
Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.Breast Cancer Res. 2024 May 15;26(1):78. doi: 10.1186/s13058-024-01818-5. Breast Cancer Res. 2024. PMID: 38750591 Free PMC article.
-
A tool with many applications: vesicular stomatitis virus in research and medicine.Expert Opin Biol Ther. 2020 Oct;20(10):1187-1201. doi: 10.1080/14712598.2020.1787981. Epub 2020 Jul 9. Expert Opin Biol Ther. 2020. PMID: 32602788 Review.
References
-
- Bishnoi S, Tiwari R, Gupta S et al (2018) Oncotargeting by vesicular stomatitis virus (VSV): advances in cancer therapy. Viruses 10(2)
MeSH terms
LinkOut - more resources
Full Text Sources
Medical